Is Korro Bio, Inc. (KRRO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 42.5% / 30% | 119.8% / 30% | 1.6% / 30% | 372.96% / 5% | ✗ NOT HALAL |
| DJIM | 42.5% / 33% | 119.8% / 33% | 1.6% / 33% | 372.96% / 5% | ✗ NOT HALAL |
| MSCI | 19.8% / 33% | 55.7% / 33% | 0.7% / 33% | 372.96% / 5% | ✗ NOT HALAL |
| S&P | 42.5% / 33% | 119.8% / 33% | 1.6% / 33% | 372.96% / 5% | ✗ NOT HALAL |
| FTSE | 19.8% / 33% | 55.7% / 33% | 0.7% / 50% | 372.96% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -1229.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -110.7% | |
| Return on Assets (ROA) | -32.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$79M |
| Free Cash Flow | -$79M |
| Total Debt | $43M |
| Debt-to-Equity | 84.5 |
| Current Ratio | 6.9 |
| Total Assets | $114M |
Price & Trading
| Last Close | $10.91 |
| 50-Day MA | $11.43 |
| 200-Day MA | $18.66 |
| Avg Volume | 238K |
| Beta | 2.5 |
|
52-Week Range
$5.20
| |
About Korro Bio, Inc. (KRRO)
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Korro Bio, Inc. (KRRO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Korro Bio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Korro Bio, Inc.'s debt ratio?
Korro Bio, Inc.'s debt ratio is 42.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 19.8%.
What are Korro Bio, Inc.'s key financial metrics?
Korro Bio, Inc. has a market capitalization of $150M, and revenue of $6M. Return on equity stands at -110.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.